Request for Free Sample

Onychomycosis Treatment Market Size & Trends:

The Onychomycosis Treatment Market was valued at USD 3.76 billion in 2024 and is expected to reach USD 5.40 billion by 2032, growing at a CAGR of 4.67% over the forecast period of 2025-2032.

The global onychomycosis treatment market is exhibiting significant growth due to an increase in the prevalence of fungal nail infections, an increasing geriatric population, and the increased awareness of personal hygiene and nail health. The rise in demand for minimally invasive treatment options, together with the proven track record of topical and oral antifungal therapies are additional factor propelling the growth of this market. Increasing numbers of regulatory approvals for a new product and better access to dermatologicals are also likely to propel the growth of the onychomycosis market trends during the forecast period in developing regions.

The U.S. onychomycosis treatment market size was valued at USD 1.14 billion in 2024 and is expected to reach USD 1.60 billion by 2032, growing at a CAGR of 4.37% over the forecast period of 2025-2032. North America accounts for the largest share of the onychomycosis treatment market, due to a strong healthcare infrastructure, a high level of patient awareness, and a high volume of prescriptions in the U.S. The deep dermatological care and the availability of topical and oral antifungal therapies always make it a dominant market player in the region.

Onychomycosis Treatment Market Dynamics:

Drivers:

  • Increase in Onychomycosis and Fungal Infections Drives Market Growth

The Onychomycosis treatment market analysis is primarily driven by the surging global prevalence of onychomycosis. The elderly, the diabetic, the immunosuppressed, and those who have been in wet environments, such as swimmers and athletes, are particularly susceptible to this condition. The increasing prevalence of chronic diseases combined with hot, humid temperature also facilitate. Its early stages are often undiagnosed, and, as the disease progresses and becomes more difficult to manage, there continues to be an increasing need for effective therapeutic options. The growing population of patients has a direct role in propelling the demand for prescription and OTC antifungal therapy options.

Globally, onychomycosis affects approximately 4–10% of adults, 20% over the age of 60, and 50% over the age of 70, according to MDPI.

Others with comorbidities, diabetes, immunosuppression, and hemodialysis patients have rates as high as 19%–52%, highlighting an ever-expanding patient denominator.

  • Market Growth Driven by Innovations in Topical and Oral Antifungal Treatments

Improvements in efficacy and availability of topically and orally delivered antifungal agents have facilitated improved design and analyses of therapeutic options. A new generation of topical formulation protocols with greater nail penetration and enhanced adhesion properties, enabling the active ingredient to penetrate deeper in a more effective manner. As an example, they now have lacquers and medicated creams it has been designed for extended wear and high absorption. The oral side, drugs are more available, terbinafine variants carry greater bioavailability and lower potential toxicity, which increases their attractiveness to prescribers and patients. The innovations, which contribute to improved treatment outcomes and compliance, have further fueled the onychomycosis treatment market growth.

This recent randomized trial of a new topical antifungal nail solution achieved a mycological cure in 55% of patients treated versus only 2.6% of those on placebo.

Restraints:

  • Long Treatment Duration and Poor Patient Compliance are Halting the Market Growth

The prolonged time taken to cure the condition is one of the major issues in the onychomycosis treatment market trends. Patients may have to apply the medication daily for 6 to 12 months, and even longer for toenail infections, where the nail grows more slowly. Oral antifungals, although initially faster-acting, also necessitate weeks to months of continuous therapy.

Such long-term treatment inevitably contributes to poor adherence as patients stop treatment when symptoms disappear or due to inconvenience. Not all people complete the entire course of the drug, which is important for the complete removal of the fungus. Incomplete treatment can promote recurrence and development of drug resistance, leading to reduced efficacy of therapy and reduced trust in available options, both treatments and clinicians. This continues to constrain the overall growth of the market, with low adherence rates.

Segmentation Analysis:

By Type

Distal subungual onychomycosis segment dominated the market with a 42.60% in 2024, as it is the most prevalent form, occurring in patients of all ages, but is most common in older adults and individuals with diabetes or suppressed immune systems. Distal subungual onychomycosis, which starts at the nail bed and works its way upward, is the most recognized form of the nail infection. Chronicity, resistance to self-care, and progressive course increase the need for a medical solution, frequently with prescription oral antifungal agents and sustained management, and contribute to strong market leadership.

The white deep onychomycosis segment is expected to grow at the fastest rate during the forecast period due to its growing stage identification, increasing aesthetic awareness, and growing availability of effective topical therapies. This is a unique type of onychomycosis as it only involves the more superficial parts of the nail plate and is highly responsive to topical therapy if treated early. Driven by consumers and providers who want high-velocity, cosmetic-based cures, the effective topical treatments used for this form of infection are designed for rapid acquisition by businesses, driving fast-paced growth.

 By Treatment

In 2024, onychomycosis treatment market was dominated by the topical segment, which is attributed to the easy availability and ease of administering onychomycosis treatment topically and increasing preference of patients for non-invasive treatment options. Topical antifungal agents are commonly the first line of therapy in mild to moderate cases, due to limited systemic side effects and availability without prescription in many countries. Topical formulations, such as lacquers or medicated creams with enhanced nail penetration have improved efficacy and adherence in comparison to earlier preparations.

The oral treatment segment is anticipated to experience the fastest growth over the forecast period as it is more effective in treating moderate to severe or recurrent onychomycosis cases. Although topical antifungals are effective in some cases, oral antifungals such as terbinafine and itraconazole yield quicker and more consistent results by circulating in the bloodstream to get to the infection, especially in the case of deep involvement of the nail bed. Oral therapies are more favorable amongst healthcare providers due to the increasing incidence of more resistant fungal infections associated with an increasing global burden of chronic conditions, such as diabetes and immunodeficiency.

By End Use

The dermatology clinics segment dominated the onychomycosis treatment market share with a 52.04% in 2024, driven by oriented treatment along with the desire for specialized and targeted treatment. Fungal nail infections are targeted at dermatology clinics, which can provide specialized treatments, such as advanced topical therapies, laser treatment, and cosmetic nail apparatus, which are not available in primary health care facilities. These clinics have an average of shorter waiting times for appointments, which helps to individualize treatment, and follow-up for chronic diseases such as onychomycosis.

The hospitals segment is anticipated to have the highest growth over the forecast period, as they are well equipped to cater to patients with moderate to severe, recurrent, or complicated onychomycosis. This typically includes hospitalization with diagnostic testing, systemic oral antifungal therapy, and addressing comorbidities, such as diabetes and vascular disease. The rising tide of chronic diseases around the globe is placing an ever-growing demand for hospital-based intervention in many cases where topical treatment has failed.

Onychomycosis Treatment Market Regional Outlook:

North America dominated the onychomycosis treatment market with a 41.03% market share in 2024 due to the presence of a well-established healthcare infrastructure and high patient awareness, along with easy access to dermatological services in the region. Fungal nail infections are highly prevalent in the region, especially in the elderly and diabetics. Moreover, increasing penetration of key pharma companies, regular approvals of advanced topical and oral antifungal drugs, and insurance for treatment will drive the market positively. This dominance is mainly incited by the U.S., where the prescription of medication is high, along with a proactive approach in diagnosing and treating patients.

Hallux Subungual Gel (terbinafine injection) is a Novel drug delivery under Phase II in the US, suggesting a trend toward locally injected therapies and other minimally invasive therapies.

Asia Pacific represents the fastest-growing region in the onychomycosis treatment market with 5.46% CAGR as a result of increasing awareness regarding nail health, improving access to healthcare, and a rising geriatric population. The market players in countries, such as China, India, and Japan are witnessing a high demand for both over-the-counter and prescription antifungal treatments, propelled by rising per capita income and urbanization. Additionally, health systems are improving quickly, and consumers are also shifting towards hygiene and aesthetic care. The growth of advanced treatment options in this region is further aided by government initiatives and distribution networks.

Europe is a lucrative market due to the well-established healthcare system, increasing awareness about fungal nail infections, and the preference of patients for treatment that doesn’t involve invasive procedures. These factors are gradually boosting the target patient pool receiving treatment in the region due to the increasing elderly population and rising incidence of diabetes. Also, better dermatologic access and the development of topically acting antifungal medicines have enhanced the availability of early diagnostic and therapeutic measures.

Germany, France, the U.K., and Italy lead the market expansion mainly due to the strong R&D and presence large scale of large-scale pharmaceutical companies. Enhanced adoption has also resulted from favorable reimbursement policies as well as the ease of purchase of over-the-counter antifungal products. Moreover, increasing concern related to hygiene, aesthetic appeal, and general health is supporting the need for efficient onychomycosis treatment in the European region.

Latin America is demonstrating steady growth over the forecast period due to the rising awareness about fungal infections and slow progress in healthcare access. Onychomycosis is becoming more common in this country owing to the warm and humid climate of the region, along with high prevalence of diabetes and other immunocompromised states. An increase in access to public health campaigns and dermatological services has led to many patients presenting for early diagnosis and treatment.

The MEA region is exhibiting significant growth as a result of urbanization, heightened disposable incomes, and improved healthcare infrastructure in a number of nations. Awareness around personal hygiene, along with the aesthetic nature of the fungal nail infection, has increased the need for treatment, especially in developed markets, such as the UAE and Saudi Arabia.

Onychomycosis Treatment Market Key Players:

The major onychomycosis treatment market companies are Bausch Health Companies, Pfizer, Novartis, Bayer, GlaxoSmithKline, Johnson & Johnson, Cipla, Moberg Pharma, Teva Pharmaceutical Industries, Galderma, and other players.

Recent Developments in the Onychomycosis Treatment Market:

  • February 2024 – Vanda Pharmaceuticals Inc., a global biopharmaceutical industry leader, reported that the United States Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) request to test VTR-297 for the treatment of onychomycosis. This is an important development in the progression of new antifungal treatments.

  • May 2024 – Moberg Pharma AB announced that MOB-015 has obtained national marketing authorizations in all 13 European countries participating in the decentralized procedure. The local treatment is now authorized for use in adults with mild to moderate fungal nail infection (onychomycosis), broadening its availability across the European market.

    Onychomycosis Treatment Market Report Scope:
    Report Attributes Details
    Market Size in 2024 USD 3.76 Billion 
    Market Size by 2032 USD 5.40 Billion 
    CAGR CAGR of 4.67% From 2025 to 2032
    Base Year 2024
    Forecast Period 2025-2032
    Historical Data 2021-2023
    Report Scope & Coverage Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
    Key Segments • By Type (Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, Other Types)
    • By Treatment (Oral, Topical, Others)
    • By End Use (Hospitals, Dermatology Clinics, Homecare Settings, Ambulatory Surgical Centers)
    Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
    Company Profiles Bausch Health Companies, Pfizer, Novartis, Bayer, GlaxoSmithKline, Johnson & Johnson, Cipla, Moberg Pharma, Teva Pharmaceutical Industries, Galderma, and other players.